ST. LOUIS, April 27 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company whose business is public health(TM), announced today that its CEO, David W. Moskowitz MD, was awarded the 2006 Defender of Patient Safety Award in the physician category for reversing chronic kidney failure from diabetes and high blood pressure. These two diseases cause 90% of dialysis. The only alternative to dialysis is a kidney transplant.
The nation is in the middle of a dialysis epidemic. There were 200,000 dialysis patients in 2000. By 2010, there will be 300,000 patients on dialysis. The average dialysis patient now costs Medicare $100,000 a year. The average life expectancy on dialysis is only three years. Only 25,000 kidney transplants are performed each year, because there is a chronic shortage of kidneys.
The number of dialysis patients is expected to swell even faster once the Baby Boomers hit the age of 60.
Reversing chronic kidney failure means that dialysis could be prevented altogether. But public awareness is key, since reversing kidney failure was only possible early in the disease, before a patient’s serum creatinine had reached two (2). Serum creatinine is used to measure a person’s kidney function. The normal value is one (1); patients go on dialysis when it nears ten (10).
Dr. Moskowitz’s results were published in Diabetes Technology and Therapeutics, a peer-reviewed medical journal, in September, 2002. If applied nationally, Dr. Moskowitz’s method could prevent up to 90% of dialysis, and save Medicare over $22 billion a year. GenoMed owns the patents pending for this novel treatment approach.
About Missouri Watch
Missouri Watch is the State of Missouri’s leading patient and worker safety advocacy coalition headquartered in Jefferson City. http://www.missouriwatch.org
About GenoMed
GenoMed uses genomics to serve medicine(TM). The company’s primary commitment is to public health, including education. http://www.genomed.com
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed, Inc.
CONTACT: Ashley Allen, Executive Director of Missouri Watch, Inc.,+1-866-676-7474, or David W. Moskowitz MD, CEO of GenoMed, +1-314-983-9938,dwmoskowitz@genomed.com
